Highly enantioselective production of a chiral intermediate of sitagliptin by a novel isolate of Pseudomonas pseudoalcaligenes

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Thera

(2014) Hidetaka Yokoh et al.   Journal of Diabetes Investigation

Efficient synthesis of sitagliptin phosphate, a novel DPP-IV inhibitor, via a chiral aziridine intermediate

(2013) Xianhua Pan et al.   TETRAHEDRON LETTERS

Engineering the third wave of biocatalysis

(2012) U. T. Bornscheuer et al.   NATURE

Asymmetric synthesis of (−)-(R)-sitagliptin

(2012) Stephen G. Davies et al.   TETRAHEDRON LETTERS

Laboratory Evolution of Stereoselective Enzymes: A Prolific Source of Catalysts for Asymmetric Reactions

(2010) Manfred T. Reetz   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

The asymmetric synthesis of Sitagliptin, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

(2010) Feng Liu et al.   JOURNAL OF CHEMICAL RESEARCH-S

Biocatalytic Asymmetric Synthesis of Chiral Amines from Ketones Applied to Sitagliptin Manufacture

(2010) C. K. Savile et al.   SCIENCE

A practical synthesis of trifluorophenyl R-amino acid: The key precursor for the new anti-diabetic drug sitagliptin

(2009) Li Li Zeng et al.   CHINESE CHEMICAL LETTERS

Highly Efficient Asymmetric Synthesis of Sitagliptin

(2009) Karl B. Hansen et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

MEGA: A biologist-centric software for evolutionary analysis of DNA and protein sequences

(2008) S. Kumar et al.   BRIEFINGS IN BIOINFORMATICS

Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials

(2008) Avraham Karasik et al.   CURRENT MEDICAL RESEARCH AND OPINION